Journal article · 2026 · Open access
Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF )
Clinical Pharmacology & Therapeutics · Published 3 November 2026 · DOI 10.1002/cpt.70540
In brief
“Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF )” is a 2026 journal article by Hossam Sharaf and 3 co-authors, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 0 citations as of 17 November 2026. It is open access: the full text is free to read at Clinical Pharmacology & Therapeutics.
- Citations
- 0
- References
- 44
- Authors
- 4
Abstract
Early adjunctive therapies may improve decongestion and symptoms in acute heart failure. This trial compared dapagliflozin with acetazolamide when initiated early, focusing on dyspnea relief as the primary outcome and decongestive, diuretic, natriuretic, and safety outcomes. In this randomized, active-controlled trial, 108 adults hospitalized with acute heart failure, dyspnea, and objective evidence of congestion requiring intravenous loop diuretics were randomized to receive dapagliflozin 10 mg (N = 55) or acetazolamide 500 mg (N = 53) once daily for 3 days alongside standard care. The primary endpoint was the between-group difference in 72-hour dyspnea visual analog scale area under the curve. Secondary endpoints included successful decongestion within 3 days, diuretic and natriuretic responses, the relative change in N-terminal pro-B-type natriuretic peptide levels from baseline to day 3, and safety. Acetazolamide produced a significantly lower 72-hour dyspnea area under the curve than dapagliflozin (2647.9 ± 1213.8 vs. 2988.7 ± 1196.7 mm × hour; P = 0.048). It increased cumulative urine output over 72 hours (12,200 vs. 10,000 mL; P = 0.019) and total natriuresis over 48 hours (824.7 vs. 547.9 mmol; P = 0.001). Dapagliflozin achieved a larger reduction in N-terminal pro-B-type natriuretic peptide at 72 hours (-34.2% vs. -25.0%; P = 0.003). Safety events were infrequent and similar. In conclusion, acetazolamide provided greater dyspnea relief, diuresis, and natriuresis, whereas dapagliflozin produced a larger short-term reduction in N-terminal pro-B-type natriuretic peptide. Further studies are needed to validate these findings. Trial registration: https://clinicaltrials.gov/study/NCT06783166.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Sharaf, H., Wadie, M., Mansour, N. O., & Shams, M. E. E. (2026). Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF ). Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70540
MLA 9
Sharaf, Hossam, et al. “Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF ).” Clinical Pharmacology & Therapeutics, 2026. https://doi.org/10.1002/cpt.70540.
Chicago
Sharaf, Hossam, Moheb Wadie, Noha O. Mansour, and Mohamed E. E. Shams. 2026. “Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF ).” Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70540.
Harvard
Sharaf, H. et al. (2026) ‘Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF )’, Clinical Pharmacology & Therapeutics. doi:10.1002/cpt.70540.
IEEE
H. Sharaf, M. Wadie, N. O. Mansour, and M. E. E. Shams, “Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF ),” Clinical Pharmacology & Therapeutics, 2026, doi: 10.1002/cpt.70540.
BibTeX
@article{sharaf2026dapagliflozin,
title = {{Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF )}},
author = {Sharaf, Hossam and Wadie, Moheb and Mansour, Noha O. and Shams, Mohamed E. E.},
journal = {Clinical Pharmacology \& Therapeutics},
year = {2026},
doi = {10.1002/cpt.70540},
url = {https://doi.org/10.1002/cpt.70540}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- dapagliflozin
- acetazolamide
- acute heart failure
- dyspnea
- decongestion
- diuresis
- sodium excretion
- N-terminal pro-brain natriuretic peptide
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Sharaf, H., Wadie, M., Mansour, N. O., & Shams, M. E. E. (2026). Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial ( CHOICE ‐ AHF ). Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70540
How many times has this paper been cited?
0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Clinical Pharmacology & Therapeutics: sign in and open the PDF from this page.
Who wrote this paper?
Hossam Sharaf, Moheb Wadie, Noha O. Mansour, Mohamed E. E. Shams.
What is the DOI of this paper?
10.1002/cpt.70540, permanently at https://doi.org/10.1002/cpt.70540. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.